In most of medicine, a prior authorization delay is an inconvenience. In oncology, it is a clinical event. When a patient’s cancer is progressing, the days spent waiting for a payer to approve a regimen the oncologist has already chosen are days the disease keeps moving.
That is why prior authorization hits oncology harder than almost any other specialty — not because oncologists face more authorizations in raw count, but because the stakes of each delay are so much higher.
The numbers in oncology
The American Society of Clinical Oncology has surveyed its members on exactly this. The findings are stark:
- 96% of oncologists report that prior authorization delays patient care.
- 68% report delays of five days or more.
- 80% have seen prior authorization lead to disease progression.
- 33% report that patients abandoned treatment while waiting on an authorization.
These sit on top of the burden every specialty carries. The AMA’s 2024 Prior Authorization Physician Survey found physicians complete an average of 39 prior authorizations per week and spend roughly 13 hours per week on them — and that 93% say PA delays necessary care.
In oncology, that general friction collides with the most time-sensitive disease category in medicine.
Why oncology is different
A few structural features make prior authorization especially punishing here:
- Buy-and-bill infusions. Many oncology drugs are administered in-office and billed under the medical benefit. The infusion chair can’t be scheduled until the authorization clears — so an auth delay is an empty chair, lost revenue, and a patient still waiting.
- Recurring re-authorizations. A single regimen often requires re-authorization every few cycles. One approval quietly becomes a recurring chore, and a lapsed re-auth interrupts active therapy.
- Payer-by-payer documentation. Each payer wants different documentation for the same NCCN-supported regimen. Staff assemble the same clinical story in a dozen different shapes.
- Peer-to-peer reviews. When a regimen is questioned, an oncologist is pulled off the floor to defend — by phone — a treatment that is already standard of care.
What it costs
The cost shows up in three places at once. There’s the clinical cost — disease progression and abandoned treatment, the outcomes ASCO measured directly. There’s the staff cost — CAQH pegs a manually processed prior authorization at about $10.81, and oncology practices run a high volume of them across complex, recurring regimens. And there’s the practice cost — infusion schedules that stall, revenue that slips, and clinician time spent on hold instead of in the exam room.
None of these are the cost of denial. They’re the cost of delay on authorizations that were largely going to be approved anyway.
How to cut the wait
Prior authorization in oncology is a documentation-and-matching problem wearing the costume of a clinical one. The oncologist has already made the decision; the payer is asking for proof in a specific format. That is exactly the kind of work software should do.
Artificer Health treats prior authorization as a solvable engineering problem:
- Assemble the packet automatically from the patient’s record — diagnosis, staging, prior therapies, and the supporting clinical detail each regimen requires.
- Match it to the payer’s policy so the submission meets that specific payer’s criteria the first time.
- Submit and track end-to-end, surfacing re-authorization deadlines before they lapse instead of after.
The goal is simple: first-pass approvals measured in minutes, infusion chairs that stay full, and oncologists who spend their time treating cancer instead of documenting permission to.
Sources: ASCO 2024 Prior Authorization survey; ASTRO 2024; AMA 2024 Prior Authorization Physician Survey (n=1,000); CAQH 2023 Index.